Mast cell specific immunological biomarkers and metabolic syndrome among middle-aged and older Chinese adults.

The main aim of this study is to explore whether these mast cell specific immunological biomarkers [immunoglobulin E (IgE), chymase and tryptase] is an independent risk factor of MetS and whether the combined action of these biomarkers increased the associations with MetS. Three mast cell-specific immunological biomarkers were measured using enzyme linked immunosorbent assay (ELISA). One-way analysis of covariance and logistic regression models were used for analyzing the associations between immunological biomarkers with MetS. A total of 340 participants, 82 (24.1%) individuals had diabetes mellitus, 31 (9.1%) had MetS (without diabetes mellitus) and 110 had MetS plus diabetes mellitus. After adjusting by multivariable (age, gender, smoking, and family history for hypertension), compared with no diabetes mellitus or MetS group (reference group), hs-CRP was associated with diabetes mellitus [OR (odds ratio): 2.29 (1.15-4.57, 95% CI (confidence interval), p=0.019] and MetS plus diabetes mellitus [OR: 2.20 (1.05-4.61, 95% CI), p=0.036], IgE was associated with MetS plus diabetes mellitus [OR: 2.38 (1.13-5.02, 95% CI), p=0.023]. After adjusting by multivariable, compared with reference group, most of combined elevated inflammatory or immunological biomarkers were significantly associated with diabetes mellitus or MetS with or without diabetes mellitus. Patients with established diabetes mellitus or MetS had different inflammatory or immunological cytokine profile (such as hs-CRP, IgE, chymase, tryptase), which indicated that there is an alteration in the function of the immune system in diabetes mellitus or MetS patient. But these results are requested to be further demonstrated for large sample population-based cohort study.